ASN Publications

Journal Logo

​​​​ASN JOURNAL PORTFOLIO POLICIES AND INSTRUCTIONS

​ASN Journal Author Policies

Equality

ASN Journal Policy on Scientific Misconduct

Ethical Issues

Authorship

Duplicate Submission or Prior Publication

Image Forensics

Plagiarism

Preprints

Registry, Data Sharing, And Adherence Policies

Declaration Policies

Format and Process

Manuscript Components – Original Research Articles

Policies

Publication Fees and Open Access

Publication Fees

Open Access

Author Publication Toolkit

CJASN Instructions for Authors

JASN Instructions for Authors

K360 Instructions Authors

K360 License to Publish

Back to Top

EQUALITY

The ASN journal portfolio fully supports ASN's efforts to achieve equality to reduce the adverse impact of racism, especially on health and in health care. ASN journals are working to improve equity in the following ways and will continue to identify other avenues to reduce systemic racism:

  1. Diversifying the editorial board to better address and reflect diverse populations.
  2. Creating collections of original content highlighting systemic racism and care disparities.
  3. Soliciting invited articles on:
    1. Health care crises around the globe, including a focus on patient voices; and
    2. Special series addressing racism in health care, as well as institutional, educational, and professional settings.
  4. Making all articles freely accessible to researchers in developing countries through the Health Inter Network Access to Research Initiative (HINARI).

To help support this important goal, authors, Editors, and readers are encouraged to share their ideas about additional opportunities for inclusion with Shari Leventhal, Executive Editor, at [email protected].

Back to Top

ETHICAL ISSUES

ASN Journal Policy on Scientific Misconduct

The ASN journal portfolio fully upholds the highest standards of peer review and academic publishing. The work of authors and reviewers contributes to the common aim of understanding the latest advances in basic, clinical, and translational research. In very rare instances, Editors receive notification or allegations of misconduct related to studies submitted to ASN journals, and the process for responding to such notification is detailed below.

Concerns Raised Before Publication: If a reviewer or a coauthor raises a concern about a manuscript that is undergoing peer review and the Editor-in-Chief agrees, the journal will notify the author(s) and request a response to the concerns. (Such concerns include, but are not limited to, questions regarding plagiarism, duplicate publication, access to data, integrity of data, and undeclared conflicts of interest.) In most instances, these concerns are readily addressed and resolved and involve honest errors or differences in interpretation, rather than any intent to deceive.

If the authors do not respond satisfactorily to the concerns raised, or if the Editor-in-Chief is presented with evidence that indicates serious concerns regarding the conduct of the study, then the Editor-in-Chief will notify the Chair of the ASN Publications Committee and will determine a course of action, in part determined by applicable laws, which may include any or all of the following:

  1. Rejecting the manuscript;
  2. Prohibiting future submissions from the authors of the manuscript for a specified period;
  3. Obtaining an advisory opinion from the Committee on Publication Ethics (COPE);
  4. Reporting their concerns to the authors' institutions;
  5. Reporting their concerns to the funding agency; and or
  6. Reporting their concerns to the Office of Research Integrity or other authorized investigative agency.

If the matter has been deemed serious enough to warrant the attention of the ASN Publications Committee, the Chair will keep the ASN President informed of all developments.

Concerns Raised After Electronic and/or Print Publication: If questions are raised by a reader regarding a published study and the Editor-in-Chief agrees, then the journal will notify the author(s) and request a response to the stated concerns. (Such concerns include, but are not limited to, questions regarding plagiarism, duplicate publication, access to data, integrity of data, and undeclared conflicts of interest.) In most instances, these concerns are readily resolved and involve honest errors or differences in interpretation, rather than any intent to deceive.

If the authors do not respond satisfactorily to the concerns raised, or if the Editor-in-Chief is presented with evidence that indicates serious concerns regarding the conduct of the study, then the Editor-in-Chief will notify the Chair of the publications committee and determine a course of action, in part determined by applicable laws, which may include any/or all the following:

  1. Reporting their concerns to the authors' institutions;
  2. Prohibiting future submissions from the authors of the manuscript for a specified period;
  3. Obtaining an advisory opinion from the Committee on Publication Ethics (COPE);
  4. Reporting their concerns to the funding agency;
  5. Reporting their concerns to the Office of Research Integrity or other authorized investigative agency;
  6. Publishing a statement of concern in the journal;
  7. Issuing a retraction; and/or
  8. Notifying any other publication involved (in the case of duplicate publication or plagiarism).

If the matter is deemed serious enough to warrant the attention of the publications committee, the Chair will keep the ASN President informed of all developments.

Back to Top

Authorship

ASN journals have adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the current update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Authorship credit should be based on (1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work pre- and post-publication. The full text of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals is available at https://www.icmje.org/.

Study Group Authors: If the author list includes study group(s), submitting authors must provide a list of the participating study group(s) and contributors in the manuscript and the online submission form. The list may contain a collaboration of individuals (e.g., investigators) and/or the name of an organization (e.g., a laboratory, educational institution, corporation, or department) and its members. If the list of group members' names exceeds 4250 characters, the group members' names will appear in the Supplemental Material and will still be indexed in PubMed.

Authorship Contributions: ASN journals require submitting authors to include authorship contributions during submission by utilizing Contributor Roles Taxonomy (CRediT). CRediT provides several benefits, including enabling visibility and recognition of the different contributions of researchers. Additional information is available at https://credit.niso.org/​.

Acknowledgments: For author contributors, ASN journals have adopted this statement from the Annals of Internal Medicine: “When used, professional writing assistance must be acknowledged. If those assisting with the writing do not meet criteria for authorship, their contributions should be noted in the acknowledgments." Additional information is available at https://www.acpjournals.org/journal/aim/authors#preparing-manuscripts-for-submission.

Back to Top

Duplicate Submission or Prior Publication

During submission, authors must state that neither the manuscript nor any significant part of it is under consideration for publication elsewhere or has appeared elsewhere in a manner that could be construed as a duplicate or prior publication of the same, or similar, work. Abstracts for scientific meetings are not considered previous publication but should be cited in the Acknowledgments section of the manuscript. Should there be doubt concerning prior publications, the title page and abstract of such material and of related manuscripts submitted for publication at other journals must be included with the submitted manuscript. Posting of un-refereed manuscripts to a community preprint server by the author will not be considered prior publication; see the “Preprints" section below for additional information.

Back to Top

Image Forensics

ASN journals require that images submitted and published in CJASN, JASN, or Kidney360 be as close as possible to the original images, with minimal processing. Image forensics programs are used to detect selective processing. For guidance on image integrity, ASN journals encourage authors to review Nature Research's editorial policies: https://www.nature.com/nature-portfolio/editorial-policies/image-integrityrch/editorial-policies/image-integrity. Prior to publication, all images are screened for potential manipulation and any findings are reviewed by the Editors. The respective journal will contact authors directly should image manipulation concerns arise.

Back to Top

Plagiarism

ASN journals utilize Crossref Similarity Check, powered by iThenticate, to screen for potential plagiarism (including self-plagiarism) prior to manuscript acceptance. The respective journal will contact authors directly should plagiarism concerns arise.

Back to Top

Preprints

Posting of un-refereed manuscripts to a community preprint server by the author will not be considered prior publication, up until acceptance, provided that the following conditions are met:

  1. During submission, authors must acknowledge preprint server deposition and provide associated accession numbers and/or digital object identifiers (DOIs); and
  2. The preprint server should meet NIH standards for interim research product repositories as available on the NIH website: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-050.html.

CJASN, JASN, and Kidney360 accept preprint manuscript submissions directly from medRxiv and bioRxiv. Authors do not have to spend time reloading manuscript files and reentering author information during submission. Authors can visit https://www.medrxiv.org/submit-a-manuscript or https://www.biorxiv.org/submit-a-manuscript to submit their preprint transfers to CJASN, JASN, or Kidney360.

Back to Top

Registry, Data Sharing, and Adherence Policies

Requirement for Registration of Clinical Trials: A clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. As a condition of consideration for publication, ASN journals require registration in a public trial registry. Trials must be registered before the onset of patient enrollment. This policy applies to any clinical trial. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt. ASN journals do not advocate a specific registry, but registration must be with a registry that meets the following minimum criteria:

  1. Accessible to the public at no charge, searchable by standard electronic (internet-based) methods, open to all prospective registrants free of charge or at minimal cost, validation of registered information, and identification of trials with a unique number.
  2. Provide information on the investigator(s), the research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing, or closed), and funding source(s).

The registration number and the date of registration must be provided during manuscript submission and will be added to the abstract during the production process prior to publication.

Examples of registries that meet ICMJE approval are listed below. This registries list is current as of October 19, 2020, and is subject to change. ASN journals will also review articles registered elsewhere on a case-by-case basis.

  1. www.anzctr.org.au/
  2. www.clinicaltrials.gov/
  3. www.isrctn.com/
  4. https://www.umin.ac.jp/ctr/index.htm
  5. https://www.who.int/clinical-trials-registry-platform/network/primary-registries/netherlands-trial-registry-(ntr)
  6. https://eudract.ema.europa.eu/
    (new registrations after June 20, 2011)

Animals: For all animal studies, authors must state adherence to the NIH Guide for the Care and Use of Laboratory Animals or the equivalent. Authors reporting animal studies are encouraged to refer to the ARRIVE guidelines: https://www.nc3rs.org.uk/3rs-resources. For studies that report several experimental series, inclusion of a supplemental table summarizing key features of all experimental series is encouraged. The table should list the series, animals used, the intervention, the sample size, outcome measures, whether there was experimenter or observer blinding, and figure and table numbers for results.

Antibodies: A description of all antibodies used must be included in the Methods section, providing the source and catalog/clone number for commercial antibodies or a description/reference to a description of the generation of custom antibodies. Steps to verify specificity must be described.

Cell Lines: Authors must describe the source of all cell lines utilized. As appropriate, include information regarding authentication of cell lines.

Back to Top

Declaration Policies

Animal Experimentation: For all animal experimentation described in the manuscript, ASN journals require that the Methods section include a statement of adherence to the NIH Guide for the Care and Use of Laboratory Animals or an international equivalent. For the full text of the NIH guidelines, see https://oacu.oir.nih.gov/regulations-standards.

Institutional Review Board or Ethics Committee Oversight: For all clinical experimentation, indicate approval by an Institutional Review Board or equivalent Ethics Committee with oversight authority for the protection of human research subjects within the Methods section. If the study is deemed exempt from Institutional Review Board or Ethics Committee approval, provide the reason for exemption.

Declaration of Helsinki: ASN journals require that authors state in the Methods section adherence to the Declaration of Helsinki. For the full text of the Declaration of Helsinki, see https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. 

Declaration of Istanbul: The purpose of the Declaration is to combat organ trafficking, transplant tourism, and transplant commercialism and to encourage adoption of effective and ethical transplantation practices around the world. ASN journals require that studies related to clinical organ transplantation include the following wording in the Methods section: “The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the 'Declaration of Istanbul on Organ Trafficking and Transplant Tourism.'" The Declaration of Istanbul is available at https://doi.org/10.2215/CJN.03320708.

Organs from Executed Prisoners: ASN journals do not accept manuscripts whose data derive from transplants involving organs obtained from executed prisoners.

Back to Top

FORMAT AND PROCESS

Formatting: For Original Research manuscripts, ASN journals will consider initial submissions that are not formatted according to the journal's specifications. Invited material should adhere to the formatting requirements indicated in the submission invitation. The Editors recommend downloading the latest style list from EndNote to ensure proper reference formatting. Additional formatting information is available in the Instructions for Authors for each respective journal.

Style Guide: ASN journals follow the American Medical Association (AMA) style guide, which includes updated nomenclature for kidney function and disease, as developed during KDIGO's Consensus Conference on Nomenclature for Kidney Function and Disease. See details here: https://doi.org/10.1016/j.kint.2020.02.010.

Back to Top

Manuscript Components (Original Research Articles):

  • Cover letter (optional but encouraged)
  • Title page
  • Structured Abstract
  • Introduction
  • Methods
  • Results
  • Discussion
  • Disclosures
  • Funding*
  • Acknowledgments
  • Author Contributions*
  • Data Sharing Statement*
  • References
  • Tables (all cited) with legends (appropriate descriptive titles)
  • Figure legends
  • Figures (individual figure files)
  • Supplemental Material PDF (optional)

*Funding, Author Contributions, and Data Sharing Statement will be added during the production process based upon information provided during submission.

Disclosures: ASN journals have adopted the ASN Conflict of Interest and Disclosure Policy. Instructions on how authors must submit their disclosures will be automatically emailed to each author at the appropriate time following submission. An ASN Journal Disclosure Form must be completed for each manuscript. The form must be submitted by each author, and it must include the unique Manuscript ID and Manuscript Title for the submitted article.

ASN journals are committed to ensuring the integrity of its scientific, educational, and research activities. ASN's Conflict of Interest Policy requires disclosure of any financial or other interest (commitment) that might be construed as resulting in an actual, potential, or perceived conflict. Authors of submissions to CJASN, JASN, or Kidney360 are required to disclose any financial relationship or commitment for the previous 36 months held by the author and any spouse/partner of the author. The form must be submitted even if an author has no disclosures to report.

Failure to comply and/or accurately and completely report the potential conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Funding: Authors should report all funding sources that were used to support the submitted work. If applicable, grant names and numbers must be provided. Information for funders who have supplied funds outside of the submitted work should be placed in the Disclosures section and not in the Funding section.

Acknowledgments: Information in the “Acknowledgments" section of the manuscript may include any/all the following:

  1. Personal thanks for technical assistance/advice; performance of special tests; use of laboratory facilities; manuscript preparation, including editorial or clerical assistance from individual persons (e.g., individuals who helped type or proofread the manuscript); critical review of the manuscript;
  2. Brief dedications;
  3. Previous presentation information;
  4. Author degree candidacy and relationship of the submitted work to the degree;
  5. References to sources of material related to the research;
  6. Role of sponsors, government agencies, or employers in the research presented; and
  7. Disclaimers (“The content of this publication does not reflect the views or policies of …").

Data Sharing Statement and Requirements: ASN subscribes to the FAIR (findable, accessible, interoperable, and reusable) data principles and requires that authors deposit data in a community-approved public repository. Information on the FAIR Guiding Principles for scientific data management and stewardship can be found at https://www.go-fair.org/fair-principles/.

Data that are the basis of research findings, including, but not limited to, the results of clinical trials, must contain the following data sharing elements:

  1. Data Type where the Data Type may be an analyzable dataset, clinical study report, clinical trial dataset, executable code, generated dataset, published material, raw data/source data, simulation codes, statistical analysis plans, or other.
  2. Repository Name is the name of the system to which the data are deposited. There are over two dozen repositories from which authors can select, including ArrayExpress Database, Github, Figshare, Dryad, NIDDK, OMICS Discovery Index, Proteome Xchange, and many more.
  3. DOI/accession number or the persistent web link to the dataset(s).
  4. Reviewer Token, when available, for confidential peer review purposes.

Datasets from systems-level analyses need to be deposited in appropriate publicly accessible archiving sites. Examples include:

  1. For DNA-based assays, such as GWAS (SNP array), whole exome sequencing (WES), or whole-genome sequencing (WGS) data, including primary genotype data and genome-wide statistics:
    1. European Genome-Phenome Archive (EGA) (https://ega-archive.org/)
    2. The Database of Genotypes and Phenotypes (dbGaP) ( https://www.ncbi.nlm.nih.gov/gap/);
  2. For RNA-based assays, such as genome-wide gene expression data (array-based, RNA-seq-based, other), including primary data and summary statistics:
    1. European Nucleotide Archive ( https://www.ebi.ac.uk/ena)
    2. Gene Expression Omnibus (GEO) ( https://www.ncbi.nlm.nih.gov/geo/).
  3. For proteomic data: PRoteomics IDEntifications database (PRIDE) ( https://www.ebi.ac.uk/pride/archive).

Publications involving machine learning are required to provide novel computer script, trained machine learning models, as well as source data used for performance evaluation at a publicly accessible website, such as Github or SourceForge. Additional information is available here.

Back to Top

POLICIES

Checklists: ASN journals expect authors to adhere to established guidelines for reporting of preclinical and clinical research. Adapted version of the checklists are available below:

  1. Checklist for Reporting of Race and Ethnicity
  2. CHEERS Checklist for Economic Evaluation of Health Interventions
  3. CONSORT Checklist for Clinical Trials
  4. COREQ Checklist for Reporting Qualitative Studies
  5. PRISMA Checklist for Systematic Reviews and meta-analysis
  6. SQUIRE Checklist (Standards for Quality Improvement Reporting Excellence)
  7. STROBE Checklist for Observational Studies
  8. TRIPOD Checklist for Prediction Model Development and Validation

  9. ​​Co​pyright: ASN journals require authors of all submitted manuscripts to assign copyright of their published contributions. The author copyright license form provides policy details. After submission of an article, each author will receive an email with a link to a copyright form. Each author must sign and date the form and submit it electronically. ASN journals recognize that for US Government employees, work created within the scope of their employ is in the public domain, and copyright transfer is not required for such work.

    Embargo: All information regarding the content and publication date of accepted manuscripts is strictly confidential. Information contained in or about accepted articles may not appear in print or electronic format, nor on the radio, television, or social media, or be released by the news media until after 5:00 PM EST on the day the article appears in the Published-Ahead-of-Print page on the journal's website or on the day the published version is mailed, whichever comes first. This policy is not meant to inhibit the presentation of the work to, or its discussion among, other researchers. For information about publication dates for specific articles, contact Christine Feheley at 202-640-4638 or email [email protected].

    Permission Requests: Permissions will be granted through CCC/Rightslink.

    Randomized Controlled Trials: ASN journals encourage authors submitting reports of randomized controlled trials to review the CONSORT Statement (http://www.consort-statement.org/). The same considerations apply for secondary analyses of randomized trials that are analyzed by treatment arm. Authors preparing reports of randomized clinical trials are expected to include a CONSORT flow diagram (http://www.consort-statement.org/consort-statement/flow-diagram) as the first figure in the manuscript. 

Transfers: If a manuscript is deemed not suitable for one ASN journal, authors can choose to have their manuscript record transferred automatically from CJASN,JASN, or Kidney360 directly into any of the other ASN journals, eliminating the repetitive steps of submission. The submitting author may indicate their transfer preference at the time of initial submission to any ASN journal. Information that comes across in the transfer includes all uploaded files, reviewer comments, and the decision letter. The transferred comments from the Editors and reviewers will be used at the discretion of the receiving journal's editorial team.

Back to Top

PUBLICATION FEES AND OPEN ACCESS

Back to Top

Publication Fees
For current publication fees, please click on Publication Fees. Discounts are available for corresponding authors who, at the time of publication, are ASN members.

Back to Top

Open Access

ASN journals recognize and support the efforts of sponsoring agencies and institutions to increase access to the research that they fund. 

Kidney360 is an open access publication. Manuscripts and other content are immediately available to the public upon publication. Kidney360 deposits all final version, issue published content to PubMed Central (PMC) on behalf of the authors. Please allow a few days after issue publication for the article to appear in PubMed and for authors to receive their PMCID. In addition to PMC deposits, Kidney360 is indexed by MEDLINE, making the work more discoverable. 

CJASN and JASN automatically deposit all articles directly to PMC, and they are made freely available per PMC requirements. If an article needs to be made freely accessible upon online publication, CJASN and JASN offer the Author Choice program. For fees, please click on Publication Fees. See the “Author Choice" below for details. Authors are encouraged to archive their version of the manuscript in their institution's repository. Authors should cite the publication reference and DOI on any deposited version and provide a link from their version to the published article on the journal's website. Journal articles are freely accessible to researchers in developing countries through the Health Inter Network Access to Research Initiative (HINARI).

Author Choice: For CJASN and JASN articles, authors may choose to have the digital posting of their manuscript freely accessible immediately upon publication through a program called “Author Choice.". For fees, please click on Publication Fees​. Authors will have the opportunity to make this choice during submission and/or when the page proofs and invoice are received.

Back to Top

AUTHOR PUBLICATION TOOLKIT

This section provides tools that authors can use to help disseminate their articles. 

Email Alerts: Authors can stay abreast of new ASN scholarly publishing articles, by seting up alerts at ASNJournals.org/alerts.

ORCID: ASN strongly encourages every author to register for and use an ORCID iD, a persistent digital identifier that distinguishes each researcher from others with similar names. An ORCID iD connects an author's affiliations, grants, publications, peer review activity, and more to ensure recognition for all contributions. Authors can register directly through each journal's submission system. Additional information is available at https://orcid.org/

Social Media: Authors are encouraged to email [email protected] with their Twitter handles post-acceptance so that they can be tagged in journal-related tweets. Be sure to follow @CJASN, @JASN_News, and @ASNKidney360 on Twitter to learn about the most recently published content. Authors are welcome to tweet about their own articles or simply retweet any @CJASN, @JASN_News, or @ASNKidney360 posts. On each article web page, Twitter and Facebook buttons are in the right-hand navigation pane to further allow the sharing of work online. 

Kudos: Use Kudos to help readers find, understand, and use the research. During submission, authors will have the opportunity to provide a short, plain language summary, a simple, nontechnical explanation or lay summary to help make it easier for people to find and understand the work. Once the article has been published, this summary will be made available through Kudos. Learn more: https://info.growkudos.com/research-stories.

Web of Science Researcher Profiles: This service helps researchers increase visibility in the worldwide research community. In a few easy steps authors can share their research achievements to attract collaborators and funders. Learn more: https://clarivate.com/products/scientific-and-academic-research/research-discovery-and-workflow-solutions/researcher-profiles/.

Back to Top

CJASN Instructions for Authors

SCOPE

The goals of CJASN's articles are to (1) rapidly and effectively communicate the most important advances in clinical and translational research in nephrology, including innovations in research methods and care delivery; (2) put these advances in context for future research directions and patient care; and (3) become an important voice on every issue that potentially affects the clinical practice of nephrology, particularly in the United States. 

ARTICLE TYPES 

Original Articles: This is the primary article type published in the journal and is limited to results of research studies undertaken in humans with kidney diseases, metabolism, hypertension, and other kidney-related issues, such as physiology and pharmacology.

CJASN encourages trainees to submit original articles for consideration in the annual CJASN Trainee of the Year prize contest. This competition recognizes outstanding original work done by trainees in the early stages of their careers in nephrology. For eligibility criteria and additional details, please visit https://journals.lww.com/CJASN/Pages/traineeoftheyear.aspx.

Research Letters: These are concise reports of innovative methods applied to, or results of, clinical research in humans with kidney diseases and hypertension.

Expedited Reports: Authors who believe that their findings are of unusual interest or importance to nephrology may request that their manuscript be considered for accelerated review and publication. Please contact Natalie Ngo, Managing Editor, at [email protected], to determine if the submission meets the criteria for Expedited Reports at CJASN.

Invited Articles: These are invited by the Editors, and specific instructions are sent with the invitations. The invited article categories are listed below with brief descriptions. If an author is interested in submitting invited material, please email the manuscript title, category, abstract and/or outline of interest to [email protected] for editorial consideration.

Kidney Case Conference (How I Treat): These articles are intended to help clinicians apply current knowledge at the bedside.

Perspectives: These are succinct articles on a wide range of issues with the potential to impact the clinical practice of nephrology.

Reviews: These articles summarize the current state of research on a given topic previously conducted in primary sources.

Editorials, Patient Voices, and Series: These articles are submitted by invitation only.

Cover Image: CJASN welcomes the submission of high-resolution cover photographs. These images should be submitted through Editorial Manager, and authors should select “Cover Image" as the Manuscript Type. The submission must include text organized into three paragraphs (250-word maximum): (1) details of the case; (2) description of the submitted images; and (3) key teaching points. The pathologist or radiologist must be included as an author of the cover image when relevant. The images must be saved as TIFF files using CMYK rather than RGB color. The resolution specification for TIFF files should be 1200 dpi for monochrome figures that are black and white and 600 dpi for CMYK color photographs. The cover can accommodate up to three images; dimensions of the image depend on the number of images:

  • One Image: Picas: 49p6 × 17p0 (Inches: 8.25" × 2.8")
  • Two Images: Picas: 24p9 × 17p0 (Inches: 4.125" × 2.8")
  • Three Images: Picas: 16p9 × 17p0 (Inches: 2.75" × 2.8")

Letters to the Editor: CJASN does not publish “Letters to the Editor." However, CJASN takes all inquiries seriously and will publish a correction as appropriate. Comments and concerns about published articles should be emailed to [email protected].

MANUSCRIPT FORMATTING AND PREPARATION

The following table summarizes the requirements for CJASN article types:

Article TypeAbstractMain Text ReferencesFiguresTablesSupplemental Material Allowed
TypeWord CountWord Count
Original ArticleStructured30030005044Yes
Research LetterNone80071 figure or tableNo
Kidney Case ConferenceNone1500*
101NoneNo
PerspectiveNone1500*
101NoneNo
ReviewUnstructured30030001005 figures and/or tablesNo
SeriesUnstructured30030001005 figures and/or tablesNo

*1200 words if manuscript has figures; tables are allowed.

Original Articles

Manuscripts must be typed in English, double-spaced, and include page numbers. Note: line numbers are autogenerated and should be excluded.

Restrict the use of abbreviations to terms that are common in clinical nephrology (CKD, AKI, and eGFR) and used frequently throughout the manuscript. Define each abbreviation at first use in the manuscript text and in each figure and table.
 

Manuscript Components:

  • Cover letter (optional but encouraged)
  • Title page
  • Structured Abstract
  • Introduction
  • Methods
  • Results
  • Discussion
  • Disclosures
  • Funding*
  • Acknowledgments
  • Author Contributions*
  • Data Sharing Statement*
  • References
  • Tables (all cited) with legends (appropriate descriptive titles)
  • Figure Legend
  • Figures (individual figure files)
  • Supplemental Material PDF (optional)

 
*Funding, Author Contributions, and Data Sharing Statement will be added during the production process based upon information provided during submission.

Cover letter: A cover letter is optional but encouraged. It may be used to explain unusual circumstances of a submission, such as similarity to and differences from other work published or previously submitted.

Title page: The title page should include the manuscript title; all authors' full names (first name, middle initial, last name); highest academic degrees and affiliations; the name, address, telephone number, and email address of the corresponding author; the word count for the abstract; the word count for the text, excluding references; and the number of figures and tables.

Title: The title of the manuscript should be nondeclarative and descriptive of the work, should be 15 words or less, and can include a subtitle to describe the study type (e.g., randomized controlled trial or systematic review and meta-analysis). In addition, please include a running head of 7 words or less.

Abstract: The abstract should consist of four paragraphs labeled as follows:
•  Background
•  Methods
•  Results
•  Conclusions

The use of abbreviations is strongly discouraged. Any abbreviations used in the abstract must be defined. Restrict the conclusions to those directly supported by the study data.

Methods: Describe the study design, population(s), exposure(s) or intervention(s), primary outcome, and analytic methods. Authors are encouraged to ensure that the description of the study design, analytic approach, and presentation of results meets the standards for publication by reviewing the relevant checklist(s) available.

CJASN encourages authors to use accurate and inclusive language to describe race and ethnicity in research. For additional guidance, see the article “Use of Race in Kidney Research and Medicine: Concepts, Principles, and Practice."
 
Results: Follow these guidelines for the presentation of data within the text, tables, and figures:

•  Please include the most relevant numeric data, such as sample size, numbers of events, important unadjusted or raw values such as event rates or distributions of exposure or outcome variables, and key measures of association with estimates of statistical confidence (such as 95% confidence intervals).
•  All descriptive data for patients should be presented to the decimal place commonly used in clinical practice (such as age and estimated glomerular filtration rate in whole numbers, hemoglobin and albumin to one decimal place).
•  For descriptive data, percentages >1% should be presented as whole numbers. Should authors prefer to make an exception, please justify.
•  The use of P values for describing intergroup differences when describing the study cohort, such as the data presented in Table 1 of the manuscript, is strongly discouraged for observational studies and not allowed for prespecified analyses of randomized controlled clinical trials.
•  For parameter estimates (e.g., relative risks, hazard ratios, b values), use 95% confidence intervals whenever possible rather than P values.
•  Do not use “NS" for P values; provide the actual P values.
•  P values should have only two significant decimal places; however, lower values (e.g., 0.002) are acceptable. Values smaller than 0.001 should be listed as <0.001.
•  All laboratory data should be presented using US conventional units.
•  For each table and figure, provide sufficient context for readers to interpret the results without extensive reference to the accompanying text by using titles that clearly define the population, exposure, and outcome assessed, as well as footnotes that define cell contents, all abbreviations, and any unusual statistical approaches.

References: Limit references to 50 for Original Articles. CJASN follows the American Medical Association citation style. The Editors recommend downloading the latest style list from EndNote to ensure proper referencing. The names of all authors should be given unless there are more than 6, in which case the names of the first 3 authors should be given, followed by “et al." Journal names should be abbreviated according to the BIOSIS list of serials. Journal articles and books:

1. Senev A, Lerut E, Coemans M, Callemeyn J, Copley HC, Claas F, et al. Association of HLA mismatches and histology suggestive of antibody-mediated injury in the absence of donor-specific anti-HLA antibodies. Clin J Am Soc Nephrol. 2022;17(8):1204–1215 doi: 10.2215/CJN.00570122.
2. Patton MQ: Qualitative Research & Evaluation Methods. Sage Publications; 2002.

A reference citing the United States Renal Data System must be to the original source data available at www.usrds.org​.

Tables: Tables must be cited in the text, in numerical order, using Arabic numerals. Every abbreviation must be defined in every table. Authors should provide all relevant units.

Figure Legend and Figures: Figures must be cited in the text, in numerical order, using Arabic numerals. Figures of quality sufficient for accurate peer review may be included in the main manuscript file for initial submission. Guidance on preferred file types and format will be included in the decision letter.

Supplemental Material: Authors may submit Supplemental Material to accompany their article for online publication. This material should be important but not essential to the understanding and interpretation of the article. The material should be original, not previously published, and nonrepetitive of the material in the article.

The Supplemental Material should begin with a table of contents listing all elements included. The table of contents for the Supplemental Material should also be listed in the main manuscript following the Acknowledgments. Supplemental tables should be listed in numerical order beginning with “Supplemental Table 1." Supplemental figures should be listed in numerical order beginning with “Supplemental Figure 1." Upload all Supplemental Material (except for spreadsheet documents and video files) as a single indexed PDF file. Questions regarding relevancy of Supplemental Material may be emailed to [email protected].

Supplemental Material will be made available to Editors and peer reviewers during the review process but is not subjected to the same scrutiny as the main manuscript. If the manuscript is accepted for publication and the Editors deem the Supplemental Material appropriate for online publication, it will be posted online at the time of publication of the article. Unlike the manuscript, Supplemental Material will not be edited or formatted during the production process; thus, authors are responsible for the accuracy and presentation of all such material.

Visual Abstracts: The CJASN editorial team will create a Visual Abstract following a minor revision decision and will forward it to the corresponding author for review and concurrence. Authors are asked to respond as soon as possible to maintain the publication schedule.

PEER REVIEW PROCESS

Peer review at CJASN is a two-step process. The first step is an internal peer review. Each manuscript is read independently by two or more Editors and is assessed for the extent to which the findings advance the understanding of the field, as well as internal and external validity of the study. If at least one of the Editors recommends the manuscript move forward, it goes to the second step of external peer review. About one third of manuscripts are sent for external peer review. Given the volume of submissions, it is not possible for CJASN to provide narrative comments from the first step of internal review.

All manuscripts sent for external peer review are reviewed by at least two reviewers, in addition to an Associate Editor. Based on the reviewers' comments and recommendations, and in consultation with the entire editorial team, a decision is made to allow the authors to revise and resubmit (either as a major or minor revision) or to reject and not consider the manuscript further. Manuscripts should be resubmitted within 21 days for a minor revision and 45 days for a major revision.

Revised manuscripts are sent out for review again at the discretion of the Associate Editor. Based on the authors' revisions and the reviewers' comments, a decision is made to accept, request additional revisions of, or reject the manuscript. Note that not all manuscripts that are revised and resubmitted will be accepted.

ACCEPTED ARTICLES

Proofs: Accepted manuscripts will be copyedited, and electronic proofs will be made available for author approval. Authors will be notified by email when their proofs are ready. Please be sure to answer all queries. Only minor corrections are permitted.

Back to Top

JASN Instructions for Authors

SCOPE

JASN publishes original research reports and editorial matter in areas of basic and clinical science relevant to the broad discipline of nephrology. Subjects appropriate for JASN include renal cell biology, developmental biology of the kidney, genetics of kidney disease, cell and transport physiology, hemodynamics and vascular regulation, mechanisms of blood pressure regulation, renal immunology, renal pathology, pathophysiology of renal disease, nephrolithiasis, clinical nephrology, including dialysis and transplantation, clinical hypertension, epidemiology of kidney disease, hypertension and associated cardiovascular disease. Articles addressing health care policy and care delivery issues of relevance to nephrology are welcome.

ARTICLE TYPES 

Original Articles: Original Articles are full-length manuscripts reporting original research findings. Data presentation is a key element of Original Articles. JASN Editors strongly encourage inclusion of a simple schematic drawing in the Discussions section illustrating the main concept of the work. Manuscripts reporting extensive systematic review of existing literature and/or meta-analysis of previously published results, for example reanalysis of individual patient level data, may be submitted as Original Articles. These articles should adhere to PRISMA guidelines.

Rapid Communications: Rapid Communications are short, expedited publications of research findings of exceptional importance. This manuscript type has been established to give authors the opportunity to submit in a concise format a novel research result for expedited assessment. This category is restricted to findings of sufficient scientific or clinical urgency to justify accelerated review and publication. Articles accepted for consideration in this category will be subject to accelerated handling, with a goal of time from initial submission to online publication of less than 90 days.

Research Letters: Research Letters are short reports that may focus on brief case series or other informative, systematic observations. Individual case reports are not normally accepted unless they provide new mechanistic information.

Editorials: Editorials are invited opinion pieces, generally related to original research published in the same issue. Editorials comment on the subject area and importance of the related original research.

Perspectives: Perspectives address topical issues, controversies, recent scientific developments, or novel observations relevant to any aspect within the broad compass of nephrology and hypertension, from basic science to public policy. They may challenge dogma or present a distinctive point of view. Articles should be timely and engaging. For particularly controversial topics, the Editors may solicit a counterpoint Perspective. Perspectives may be submitted for consideration for publication without an invitation or may be solicited by the Editors. Special articles, such as summaries of proceedings and policy statements, are appropriate for this publication category. Manuscripts submitted as Perspectives will be reviewed by the Editors and may be subjected to additional peer review at the discretion of the Editors.

Reviews: Reviews summarize and interpret existing literature on topics of interest to JASN readership. Both invited and unsolicited Reviews are accepted for consideration. Authors should strive for a balanced, scholarly analysis in areas with opposing points of view. All submitted reviews are read by the Editors and, if judged potentially suitable for publication, are subjected to external peer review by at least one additional expert.

Letters to the Editors: JASN accepts Letters to the Editors about articles appearing in recent issues. Letters may be submitted that address issues in any article type. Submission of Letters within 4 months of the online publication or 2 months of the print publication of the original article is strongly encouraged. In most instances, Letters will be provided to the authors of the original article for comment.

MANUSCRIPT FORMATTING AND PREPARATION

The following table summarizes the requirements for JASN article types:

Article TypeAuthor LimitAbstractSignificance StatementMain Text ReferencesFigures
​Tables

Supplemental Material Allowed
TypeWord CountWord Count
Original ResearchNo LimitStructured250*120*3500*1008No Limit​Yes
Rapid CommunicationsNo LimitStructured2501202000**1008No Limit​Yes
Research Letters6None
80071***1**​No
Editorials2None
1000101​None
No
PerspectivesNo LimitNone 1250101***​1**
No
ReviewsNo LimitUnstructured250None3000No LimitNo Limit ​Yes
Letters to the Editor4None
4004​0 ​No

*3500 includes Abstract and Significance Statement. Methods is excluded from this word count.

**Including the abstract and significance statement

***Only one figure or one table is permissible, not both.

Manuscripts should be in English and double-spaced, with page numbers but no line numbers. JASN cannot edit manuscripts that require extensive syntactical and/or spelling revisions. The quality of the writing is reviewed along with the scientific content and can be a basis for rejection.

Manuscript Components:

•   Original Articles and Rapid Communications elements should appear in the following order:

  • Title page
  • Significance Statement
  • Structured Abstract
  • Introduction
  • Methods
  • Results
  • Discussion
  • Disclosures
  • Funding*
  • Acknowledgments
  • Author Contributions*
  • Data Sharing Statement*
  • References
  • Tables (all cited) with legends (appropriate descriptive titles)
  • Figure Legend
  • Figures (individual figure files)
  • Supplemental Material PDF (optional)**
  • Visual Abstract (required at revision)

 
*Funding, Author Contributions and Data Sharing Statement will be added by ASN staff based upon information provided during submission.
 
** Note: Supplemental Material should be submitted in a separate PDF document or supplemental spreadsheets, except for spreadsheets of “-omic" data, which should be uploaded separately as the Supplemental Spreadsheets file type.

  Research Letters should have the following elements in order: title page, integrated discussion, brief methods section, acknowledgements, disclosures, funding, references, figure legend and figure(s) or table(s).

•   Perspectives and Editorials should have the following elements in order: title page, integrated discussion, acknowledgments, disclosures, funding, references, figure legend or table.

  Reviews should have the following elements in order: title page, abstract, integrated discussion, acknowledgments, disclosures, funding, references, figure legend and figure(s) or table(s).

•   Letters to the Editors should have the following elements in order: title page, integrated discussion, acknowledgment, disclosures, funding, and references.

Significance Statement: A 120-word summary of the submitted work, the Significance Statement, is required for Original Article and Rapid Communication submissions and should be informative to the general reader of JASN, avoiding the pronoun 'we'.

It should address three questions:

1. What was previously known about the specific topic of the manuscript? This statement should not reiterate facts well known to the renal research community.
2. What were the most important findings? If studies are animals, this should be specified.
3. How does the novel information advance a new understanding of the kidney and its diseases?

Example: Fibrillary GN (FGN) is a primary glomerular disease with a poor prognosis. Currently, FGN poses substantial diagnostic challenges, in part because specific histological biomarkers of this disease have not been identified. This paper describes the discovery, using proteomics, of a new potential biomarker, DnaJ heat shock protein family (Hsp40) member B9 (DNAJB9). It demonstrates overabundance of DNAJB9 in FGN glomeruli, but not in glomeruli from patients with other glomerular diseases or from healthy subjects. The high specificity of DNAJB9 for FGN makes DNAJB9 a potentially useful diagnostic marker. Study of its function may provide important clues to the underlying pathogenesis of FGN.

Abstract: Abstracts are limited to 250 words. Abstracts for Original Articles and Rapid Communications should include the following elements, designated explicitly: Background, Methods, Results, Conclusions. Abstracts should be written for maximum clarity, with limited use of abbreviations defined within the abstract. The species used should be identified. All numbers cited in the abstract should be included in the Results section. Reviews require an unstructured abstract.
 
Visual Abstract: Visual Abstracts are brief summaries of Original Articles and Rapid Communications for online publication. They serve to summarize the work for online readers and may be used in social media postings. ​Please avoid excessive detail and clutter, keep text to a minimum, and exclude trade names, logos, or images of trademarked items in the visual abstract. Authors invited to submit a revision must provide a Visual Abstract. The visual abstract should be uploaded as an editable PPT file. Please select one of the approved templates provided. 

JASN Visual Abstract Templates.pptx
 
Methods: JASN Editors consider the Methods section a critical element in the manuscript. The information provided in the Methods section should be readable and complete enough to give the reader a fundamental understanding of what studies were performed and the core principles of the methodology. It should include, as appropriate, oversight of animal or human studies, the population studied, animals used, cell lines and/or the data resources used, the experimental design(s), outcome measures and measurement methods. The final section of the Methods should describe the statistical analytic methods used. JASN editors encourage inclusion of a table explaining the statistical methods used for each experimental series, the unit of analysis (for example per animal or per sample) and/or data type. Additional technical information about methods may be included in the Supplemental Material, but reference to Supplemental Material should not be needed to understand the core experimental steps and principles.

References: JASN Editors value good scholarship in the selection of references and evaluate reference accuracy as part of manuscript review. When citing recent research findings, authors should, in general, cite the primary paper rather than a review. Statements about clinical practice should cite systematic reviews or guidelines, when available, rather than secondary sources. When online data resources have been used to generate reference data or other critical components, references should not cite secondary sources. Citations of data resources should conform to the citation format recommended by the site (e.g., USRDS. 2017 Annual Data Report).

References should be listed in order of their appearance in the text. List all authors when the number of authors is six or fewer. When the number of authors is greater than six, use et al. for all authors over six. Journal names should be abbreviated according to the MEDLINE list of serials. Superscripted numbers in the text should be used to indicate references; these superscripted numbers must be placed immediately after a comma or period if cited at the end of a phrase or sentence. When possible, include the article DOI at the end of the reference.

Examples of reference formatting:

1. Nangaku M, Pippin J, Couser WG: Complement membrane attack complex (C5b9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 10: 2323–2332, 1999
2. May RC, Mitch WE: Pathophysiology of uremia. In: The Kidney, 5th ed., edited by Brenner BM, Philadelphia,WB Saunders, 1996, pp 2148–2169
3. Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkossy O, et al.: Chronic fluid overload and mortality in ESRD. J Am Soc Nephrol 28: 2491–2497, 2017 doi: 10.1681/ASN.2016121341

Tables: Tables must be cited in the text and should be numbered using Arabic numerals in the order first cited. Each table should appear on a separate page of the manuscript file, beginning immediately after the references. The table number and title should be included above the table, with the title providing sufficient context to interpret the data presented. Additional information, including all abbreviations used, conversion factors for international units, and any clarifications required to understand reported statistics, should be included in notes below each table. In general, a format for tables that permits portrait rather than landscape presentation is preferred, since this facilitates online viewing of the pdf version of the paper.

Figure Legend and Figures: Up to eight figures are permitted. Each figure should have no more than eight panels. Figures must be cited in the text and numbered using Arabic numerals in the order first cited. Panels should be assigned letters (e.g., Figure 1A, 1B). Each figure legend should begin with a brief title describing the figure, followed by other information needed to interpret the data, including all abbreviations used in the figure, conversion factors for international units and any clarifications required to understand reported statistics. Figure numbers and titles should appear in the figure files themselves. Guidance on preferred file types and format will be included in the decision letter.

JASN Editors discourage use of bar graphs with standard error (dynamite plunger plots) and require reformatting column bars as a dot plot in all instances when sample size is modest and individual variability is an important aspect of the data. Figures that do not meet this standard must be redrawn.

Display of original data in original form is encouraged either in the main text or in the Supplemental Material. At the discretion of the Editors and reviewers, JASN regularly asks authors to provide original data for review before acceptance. Examples include full-length gel images, patch clamp recordings, Q-PCR fluorescence curves, and genome browser maps of RNA-Seq reads.

Supplemental Material: Supplemental Material critical to the scientific story, such as technical method descriptions, additional figures, tables, video files or spreadsheet datasets, may be included. Supplemental Material will be examined by reviewers for appropriateness. If the manuscript is accepted, the Supplemental Material will be posted online along with the main paper. The Supplemental Material must begin with a Table of Contents listing all elements included. The Table of Contents for the Supplemental Material should also be listed in the manuscript before the references. In general, elements included in the Supplemental Material should be cited in the text of the main manuscript.

Upload all Supplemental Material (except for spreadsheet documents and video files) as a single indexed PDF file. Supplemental information may not be recomposed, enhanced, or manipulated after final submission. Supplemental information is posted as submitted and is not copy-edited.

PEER REVIEW PROCESS

JASN can publish only a small fraction of submitted manuscripts. Selection of manuscripts for publication is based on the importance of the scientific question, the quality and statistical strength of the data reported, the methodological approach, and the significance of the conclusions reached. All submitted manuscripts are reviewed by at least two members of the editorial team. Based on an assessment of priority, approximately two-thirds of submitted manuscripts are not sent out for external review; this decision is provided promptly to the authors. Manuscripts undergoing external review are evaluated by at least two experts and by the Editors. To expedite manuscript review, reviewers are asked to return their comments within two weeks, with the goal of providing the initial response to submitting authors within four weeks. Out of the manuscripts that are reviewed, only approximately one third are finally accepted for publication.

Authors who have received a decision letter that indicated that JASN would be interested in a revised version of their paper will receive submission instructions within their decision letter.
 

ACCEPTED ARTICLES

After a manuscript has been accepted for publication, the authors may need to upload a final set of files as a revised manuscript. The text and tables will need to be sent as a Word document (one file) and each figure in one of the following formats: EPS, AI, TIFF, or PDF. Supplemental information should be submitted in one PDF file and should include a Supplemental Table of Contents.

Manuscripts will be copyedited, and an electronic proof will be made available for author correction and approval. Authors will be notified by email when their proofs are ready. Authors must view and correct the proof using the online proof editor and return the corrected proofs within 48 hours. Be sure that all Editor or printer queries are answered. Only minor corrections are permitted. Changes to figures at proof stage will not be allowed except in rare cases. Authors will need to check coauthors' names and affiliations carefully at proof stage. Changes will not be made after the paper is posted online.

Back to Top

Kidney360 Instructions for Authors

SCOPE

Kidney360 is a general interest kidney journal that includes content from all disciplines of kidney science. Kidney360 will consider a broad array of original investigations, meta-analyses, and reviews in domains including basic, translational, clinical, epidemiologic, health policy, population science, and global health research. Kidney360 will consider original investigation that contributes in a meaningful way to kidney science. Kidney360 recognizes that establishment of reproducibility across populations defined by different stages of disease or other characteristics, and presentation of robustly designed and adequately powered clinical trials with negative results can be important contributions; Kidney360 will therefore welcome submissions of manuscripts that contribute to reproducibility and manuscripts describing negative results. Kidney360 will also consider rigorous qualitative research, and research in the areas of quality improvement, patient safety, health systems performance, and health care value.

ARTICLE TYPES

Original Investigation: The goal of Original Investigation articles is to present recent clinical and scientific advances in the field, written in a way that will be appreciated by clinical nephrologists and clinical investigators.

Innovative Technology and Methodology: The goal of these methodology papers is to describe novel methods, techniques, or significant modifications to current protocols (not minor incremental improvements). These articles may include physiological/pathological/molecular methodology, techniques developed to address clinical problems. The Editors may also solicit manuscripts providing descriptions of clinically relevant techniques. Innovative Technology and Methodology articles must describe the method in sufficient detail to enable others to implement or replicate the method or procedure

Brief Communication: These concise reports may include novel scientific findings, innovative methods applied to or results of clinical research, or negative results.

Clinical Images in Nephrology and Dialysis: Authors are welcome to submit images for consideration in our Clinical Images in Nephrology and Dialysis feature. These submissions are intended to be educational and should include a brief case description, followed by discussion and 2 to 3 bulleted teaching points. Images can include: urine microscopy, pathology, diagnostic radiology images (CT, MRI, nuclear med, etc), clinical images (skin, eyes-, etc). A statement that informed consent was obtained must also appear in the manuscript. Please attach a copy of the signed patient consent form as a supplement.

Basic Science for the Clinician: The goal of these articles is to interpret basic scientific findings for therapeutic interventions and increase the understanding of disease processes.  These articles will present balanced views on timely topics written by experts in the field. Both invited and unsolicited Basic Science for the Clinician articles will be considered for publication. We encourage you to include illustrative color figures where you think they would be helpful. No color fees will be incurred for any article published online in Kidney360.

Review Article: The goal of Review Articles is to summarize and interpret existing literature on topics of interest to clinical nephrologists and clinical investigators. Both invited and unsolicited Review Articles will be considered for publication. We encourage you to include illustrative color figures where you think they would be helpful. No color fees will be incurred for any article published online in Kidney360

Invitation Only Articles

The following article types can be submitted by invitation only. Please contact Virginia Ramsey, Managing Editor, at [email protected] with proposed topics or questions about this article type. 

Global Perspective: These brief articles have a specific global focus. They are designed to highlight the international differences in the medical management and financing of various topics in clinical nephrology, including acute and chronic kidney disease, dialysis and kidney transplantation. Please note that at least one author must be a practicing nephrologist in the country of interest. 

Debates in Nephrology: Debates in Nephrology is an article format for controversial issues and other hot topics. There will be a collection of 3 companion papers: 'Pro' and 'Con' views of a selected topic with a 'Moderator Commentary'.

Clinical Research Methods: These articles provide overviews of different clinical research methodologies and are aimed at the general readership. As such, the articles should be timely, engaging, and accessible and, when applicable, draw upon examples from the nephrology field.

Perspective: These articles address topical issues, controversies, recent scientific developments or novel observations relevant to any aspect within the broad compass of nephrology and hypertension, from basic science to public policy. Articles should be timely and engaging.

Patient Perspective: These articles address issues from the patient perspective, by the patient, relevant to a specific topic within nephrology. Articles should be timely and engaging.

Editorial: These articles will accompany certain Original Investigation articles that are identified as exceptionally important and worth highlighting for the readership. Editorials will comment on the subject area and the importance of the Original Investigation article.

MANUSCRIPT FORMATTING AND PREPARATION

The following table summarizes the requirements for Kidney360 article types:

Article TypeAuthor LimitAbstractMain Text ReferencesFiguresTablesSupplemental Material Allowed
Word CountWord Count
Original InvestigationNo Limit30030005088Yes
Innovative Technology and MethodologyNo Limit30030005088Yes
Brief CommunicationNo LimitNA15001522NA
Clinical Images in Nephrology and Dialysis3NA50051, up to 3 panelsNANA
Basic Science for the Clinician5300300010088Yes
Review5300300010088Yes
Global Perspective2NA12001022NA
Debates in Nehrology (Pro/Con)2NA12001011NA
Debates in Nephrology (Moderator Commentary)1NA100010NANA
Clinical Research Methods2NA12001011NA
Patient Perspective2NA10001011NA
Perspective2NA12001011NA
Editorial2NA15001011NA​

Manuscript Components

Original Investigation and Innovative Technology and Methodology elements should appear in the following order:

  • Cover letter (optional)
  • Title page
  • Key Points
  • Abstract (300 words or fewer) (Structured - Original Investigations) (Unstructured - Innovative Technology and Methodology)
  • Main Text (3000 words or fewer)
    • Introduction
    • Methods
    • Results
    • Discussion
  • Disclosures
  • Funding*
  • Acknowledgments
  • Author Contributions*
  • Data Sharing Statement*
  • References (50 or fewer)
  • Tables (all cited) with legends (appropriate descriptive titles) (up to 8)
  • Figure Legend
  • Figures (individual figure files) (up to 8)
  • Supplemental Material PDF (optional)

*Funding, Author Contributions, and Data Sharing Statement will be added by ASN staff based upon information provided during submission.
Original Investigation, Innovative Technology and Methodology, Basic Science for the Clinician, and Review Articles may include Supplemental Material with additional relevant supporting figures and tables.

Cover Letter: A cover letter is optional and is intended for communication directly with the Editors. It may be used to provide pertinent information for the Editors or to explain unusual circumstances of a submission, such as similarity to and differences from other work published or previously submitted.

 

Key Points: Original Investigation, Brief Communication, and Innovative Technology and Methodology articles should include up to three key points. These short, bulleted statements must identify the most relevant outcomes of the paper and provide a synopsis encapsulating the significance of the research and its implications for readers. For basic science research, authors are encouraged to utilize key points to highlight clinical relevance.

Key points should be written clearly and succinctly. When possible, avoid scientific jargon. Each key point should be no more than 140 characters, including spaces. Key points are required upon manuscript submission, immediately preceding the Abstract in both the submission form metadata and the text document.

Abstract: Original Investigations must include a structured abstract consisting of four paragraphs labeled as follows:

  • Background
  • Methods
  • Results
  • Conclusions

The use of abbreviations is strongly discouraged. Any abbreviations used must be defined in the abstract. The species used must be identified. Restrict conclusions to those directly supported by study data. Innovative Technology and Methodology, Basic Science for the Clinician, and Review Articles require an unstructured abstract. No other article types require abstracts. 

Visual Abstracts: The Kidney360 Editorial Team will create a Visual Abstract for all accepted Original Investigation articles.  They will develop the Visual Abstract to fit with the approved Kidney360 style and format.  Authors will have the opportunity to review, and edit as necessary, the Visual Abstract prior to publication.  Kidney360 may use the Visual Abstract in any Tweets and in any other appropriate materials. 

Methods

Methods: Our Editors consider the Methods section a critical element in the manuscript. The information provided in the Methods section must be readable and complete enough to give the reader a fundamental understanding of what studies were performed and the core principles of the methodology. Additional technical information about methods may be included in the Supplemental Material, but reference to Supplemental Material should not be needed to understand the core experimental steps and principles. The Methods section is not included in the word limits. It should include, as appropriate, oversight of animal or human studies, the population studied, animals used, cell lines and/or the data resources used, the experimental design(s), outcome measures and measurement methods. Authors are encouraged to ensure that the description of the study design, analytic approach and presentation of results meets the standards for publication by reviewing the relevant checklist, prior to submission.

References: Limit references to 50 per Original Investigation article. List all authors for each article cited. Journal names must be abbreviated according to the BIOSIS list of serials. ASN journals do not allow abstracts to be cited as references. The Editors recommend downloading the latest style list for the reference program you are using (e.g., EndNote). Additional reference information is available upon request.

Journal articles and books:

  1. Holden RM, Harman GJ, Wang M, Holland D, Day AJ: Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3: 105–110, 2008
  2. Patton MQ: Qualitative Research & Evaluation Methods, C 3rd Ed., Los Angeles, CA, Sage Publications, 2002

Tables: Tables must be cited in the text and must be numbered using Arabic numerals in the order first cited. Tables should be included in the article file that is uploaded for submission. Each table must appear on a separate page of the manuscript file, beginning immediately after the references. The table number and title should be included above the table, with the title providing sufficient context to interpret the data presented. Additional information, including all abbreviations used, conversion factors for international units and any clarifications required to understand reported statistics, should be included in notes below each table. In general, a format for tables that permits portrait rather than landscape presentation is preferred, since this facilitates online viewing of the pdf version of the paper.

Figure Legend and Figures: We encourage you to include illustrative color figures where you think they would be helpful. No color fees will be incurred for any article published online in Kidney360. Figures must be cited in the text, in numerical order, using Arabic numerals. Figures of quality sufficient for accurate peer review may be included in the main manuscript file for initial submission. Please be sure to use high resolution and maximum quality compression settings if creating PDFs. Guidance on preferred file types and format will be included in the decision letter.

Supplemental Material: Authors may submit Supplemental Material to accompany their article for online publication. This limited material should be important but not essential to the understanding and interpretation of the article. The Supplemental Material should be original, not previously published, and non-repetitive of the material in the article. The Supplemental Material should begin with a table of contents listing all elements included. The Table of Contents for the Supplemental Material should also be listed in the manuscript following the Author Contributions and Data Sharing Statement. Upload all Supplemental Material (except for spread-sheet documents and video files) as a single indexed PDF file.

For studies that report several experimental series, inclusion of a supplemental table summarizing key features of all experimental series is strongly encouraged. The table should list the series, animals used, the intervention, the sample size, outcome measures, whether there was experimenter or observer blinding and figure and table numbers for results.

Supplemental Material will be made available to Editors and peer reviewers during the review process but is not subjected to the same scrutiny as the main manuscript. If the manuscript is accepted for publication and the Editors deem the supplemental material appropriate for online publication, it will be posted online at the time of final publication of the article.

Supplemental Material will not be edited or formatted by journal staff; thus, authors are responsible for the accuracy and presentation of all such material. Supplemental Material will not be made available to the authors at the proof stage. Questions regarding relevancy of Supplemental Material may be emailed to [email protected].

PEER REVIEW PROCESS

The peer review at Kidney360 is a single-blind, two-step process. The first step is an internal peer review. Each manuscript is read independently by two or more Editors and is assessed for the extent to which the findings reported in the paper advance our understanding of the field as well as internal and external validity of the study. If at least one of the Editors recommends, the manuscript moves to the second step of external peer review. Not all manuscripts submitted to Kidney360 are sent for external peer review.

Manuscripts sent for external peer review will be reviewed by at least two reviewers in addition to an Associate Editor. Based on the reviewers' comments and recommendations, and in consultation with the entire editorial team, a decision will be made to allow the authors to revise and resubmit (either as a major or minor revision) or to reject and not consider further. Reviewer identities are confidential and are not shared with the authors.

Revised manuscripts should be resubmitted within 30 days for a minor revision and 90 days for a major revision. Revised manuscripts will be sent out for review again at the discretion of the Associate Editor. Based on the responsiveness of the authors and the reviewers' comments, a decision will be made to accept, request additional revisions, or reject. Note that not all manuscripts that are revised and resubmitted will be accepted.

ACCEPTED ARTICLES

Final File Format: After a manuscript has been accepted for publication, the authors will need to upload a final, clean set of files as a revised manuscript. Guidance on preferred file types and format will be included in the decision letter.

Early Access: Articles accepted by Kidney360 will first appear online in Early Access, a pre-published, unedited format. Manuscripts that are pre-published in Early Access are formally published and citable on the date of the article's appearance on the website. They are searchable in Google Scholar and other search engines. Final versions of pre-published papers will be published in a future online issue of Kidney360 after undergoing copyediting and composition. Prior to submitting files for Early Access, the authors must carefully review the entire manuscript file, paying particular attention to listing full and accurate names of all authors; including accurate institutional affiliations for each author; and including all figures, legends, and tables within the uploaded document.

Kidney360 License to Publish.pdf